* Biofrontera Inc BFRI.OQ BFRI.O is expected to show a
rise in
quarterly revenue when it reports results on August 14 for the
period ending June 30 2024
* The Woburn Massachusetts-based company is expected to
report a
40.3% increase in revenue to $8.207 million from $5.85 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Biofrontera Inc is for a
loss
of 77 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Biofrontera
Inc
is $16.00, above its last closing price of $1.25.
This summary was machine generated August 9 at 18:31 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)